Motus GI Holdings Inc (MOTS) Receives Average Rating of “Buy” from Brokerages
Shares of Motus GI Holdings Inc (NASDAQ:MOTS) have been given an average rating of “Buy” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.50.
MOTS has been the topic of a number of recent analyst reports. LADENBURG THALM/SH SH initiated coverage on Motus GI in a research report on Thursday, August 30th. They set a “buy” rating and a $14.50 target price on the stock. Oppenheimer reaffirmed a “buy” rating on shares of Motus GI in a research report on Tuesday, September 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $8.00 target price on shares of Motus GI in a research report on Tuesday, August 14th. Zacks Investment Research lowered Motus GI from a “hold” rating to a “sell” rating in a research report on Tuesday, November 20th. Finally, Dougherty & Co initiated coverage on Motus GI in a research report on Tuesday, August 28th. They set a “buy” rating and a $8.00 target price on the stock.
In other Motus GI news, CEO Timothy P. Moran purchased 15,000 shares of the stock in a transaction dated Monday, November 19th. The shares were acquired at an average price of $3.48 per share, for a total transaction of $52,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Motus GI stock opened at $3.33 on Thursday. The firm has a market cap of $52.19 million and a PE ratio of -2.60. Motus GI has a 12-month low of $3.03 and a 12-month high of $10.66.
Motus GI (NASDAQ:MOTS) last announced its earnings results on Wednesday, November 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Research analysts anticipate that Motus GI will post -1.08 EPS for the current fiscal year.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
See Also: What is a Futures Contract?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.